SENIOR LEADERSHIP

高层领导

• 批准号: 7944855
• 负责人: BRIAN LEYLAND-JONES
• 金额: $ 16.83万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-07 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944855
• 关键词: American Cancer Society; Antineoplastic Agents; Appointment; Biological Markers; Breast Cancer Treatment; Budgets; Canada; Cancer Center; Cancer Center Support Grant; Centers for Disease Control and Prevention (U.S.); Clinical; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Commit; Committee Membership; Communities; Comprehensive Cancer Center; Development; Disease; Doctor of Philosophy; Evaluation; Faculty; Foundations; Goals; Head; Health Sciences; In Vitro; Individual; Institutes; Institution; Investigational Drugs; Lead; Leadership; Malignant Neoplasms; Medical Oncologist; Medicine; Molecular; National Cancer Institute; Operative Surgical Procedures; Patient advocacy; Pharmacogenetics; Pharmacologic Substance; Pharmacology; Phase; Phase III Clinical Trials; Physicians; Population Sciences; Positioning Attribute; Principal Investigator; Protocols documentation; Public Health Nurses; Public Health Nursing; Qualifying; Recruitment Activity; Research; Resources; Role; Scientist; Screening procedure; Staging; Strategic Planning; Structure; Technology; Time; Universities; Work; advocacy organizations; authority; cancer therapy; chemotherapy; college; experience; medical schools; meetings; multidisciplinary; novel; oncology; professor; programs; therapy development; American Cancer Society; Antineoplastic Agents; Appointment; Biological Markers; Breast Cancer Treatment; Budgets; Canada; Cancer Center; Cancer Center Support Grant; Centers for Disease Control and Prevention (U.S.); Clinical; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Commit; Committee Membership; Communities; Comprehensive Cancer Center; Development; Disease; Doctor of Philosophy; Evaluation; Faculty; Foundations; Goals; Head; Health Sciences; In Vitro; Individual; Institutes; Institution; Investigational Drugs; Lead; Leadership; Malignant Neoplasms; Medical Oncologist; Medicine; Molecular; National Cancer Institute; Operative Surgical Procedures; Patient advocacy; Pharmacogenetics; Pharmacologic Substance; Pharmacology; Phase; Phase III Clinical Trials; Physicians; Population Sciences; Positioning Attribute; Principal Investigator; Protocols documentation; Public Health Nurses; Public Health Nursing; Qualifying; Recruitment Activity; Research; Resources; Role; Scientist; Screening procedure; Staging; Strategic Planning; Structure; Technology; Time; Universities; Work; advocacy organizations; authority; cancer therapy; chemotherapy; college; experience; medical schools; meetings; multidisciplinary; novel; oncology; professor; programs; therapy development

7.1 Senior Leadership of the Winship Cancer Institute Director of the Winship Cancer Institute and Associate Vice-President for the Woodruff Health Sciences Center: Brian Leyland-Jones, MD, PhD Dr. Leyland-Jones was appointed Director of Emory's Winship Cancer Institute (WCI) and Associate Director of the Woodruff Health Sciences Center (WHSC) effective January 1, 2007. He is eminently well-qualified to serve as WCI Director. A Medical Oncologist who specializes in breast cancer treatment, with a Ph.D. in Molecular Pharmacology, Dr. Leyland-Jones is a translational physician-scientist who is internationally recognized for his work in individualized cancer therapies and development of novel clinical trials. Prior to his appointment, Dr. Leyland- Jones was the Minda de Gunzberg Chair in Oncology and Professor of Medicine at McGill University in Montreal, Canada. From 1990 to 2000, he served as founding Chair of Oncology and Director of the McGill University Comprehensive Cancer Centre. From 1983-89 he was Head, Developmental Chemotherapy Section in the Investigational Drug Branch, Division of Cancer Treatment, at the National Cancer Institute. Dr. Leyland-Jones' capacity to lead the efforts at the Winship Cancer Institute is demonstrated through his prior senior positions and experiences as a premier translational scientist. During his tenure as Director of the McGill Comprehensive Cancer Centre, Dr. Leyland-Jones led development of a clinical trials operation that integrated research with five clinical trial cooperative groups and more than 40 pharmaceutical companies. Under Dr. Leyland-Jones' direction, cancer-related clinical trials at McGill included more than 100 protocols at any one time and were structured through nine multidisciplinary disease sections throughout the Cancer Centre. During his time with the NCI, he was responsible for the overall development of approximately 70 anti-cancer compounds in various stages of transition from in vitro screening to Phase III clinical trials. His expertise in pharmacogenetics in oncology clinical trials and biomarker endpoints in Phase l/ll anti-cancer agents underscores his superb background to lead the WCI and its scientific programs and shared core resources in this pursuit of NCI designation as a cancer center. In his role as Director of the Winship Cancer Institute, Dr. Leyland-Jones provides overall leadership of the WCI, its scientific programs, its shared core resources, its organization, and its administration. Dr. Leyland-Jones represents the WCI on strategic planning and leadership committees within the Woodruff Health Sciences Center and on the School of Medicine's Council of Chairs. The Authority of the Director is described in considerable detail in the previous section. Dr. Leyland-Jones controls the space, facilities, allocation of fundraising, budget, and other resources of the Winship Cancer Institute. Jointly with individual Department Chairs, he has the ability to recruit new faculty to Emory University, and with the Membership Committee he oversees membership in the WCI. As Director of a matrix Center, Dr. Leyland- Jones interacts closely with other Deans and Department Chairs in the Schools of Medicine, Nursing, and Public Health in the Woodruff Health Sciences Center and in Emory College. He also represents the WCI in collaborations with our community partners, including the American Cancer Society, CDC, Georgia Cancer Coalition, Georgia Research Alliance, Georgia Institute for Technology, Morehouse School of Medicine, GA-CORE, and other institutions throughout Georgia. Dr. Leyland-Jones provides the interface with the National Cancer Institute, with the national and local media, and with patient advocacy organizations and foundations. Dr. Leyland-Jones is committed full-time to his role as WCI Director and as Principal Investigator for the CCSG, but only 25% of his effort is supported by the CCSG budget. He will provide senior leadership, oversight, strategic planning, and on-going evaluation of progress towards meeting established goals and objectives during the course of the project period.

7.1 Winship Cancer Institute的高级领导 Winship Cancer Institute兼副总裁 伍德拉夫健康科学中心：医学博士Brian Leyland-Jones Leyland-Jones博士被任命为Emory Winship Cancer Institute（WCI）和 伍德拉夫健康科学中心（WHSC）副主任生效2007年1月1日。 他非常合格地担任WCI主任。专门研究的医学肿瘤学家 乳腺癌治疗，博士学位。在分子药理学中，Leyland-Jones博士是 转化医师科学家，因其个性化的工作而受到国际认可 癌症疗法和新型临床试验的发展。在任命之前，Leyland- 琼斯是肿瘤学的Minda de Gunzberg主席，也是McGill的医学教授 加拿大蒙特利尔的大学。从1990年到2000年，他担任肿瘤学创始主席 麦吉尔大学综合癌症中心主任。从1983 - 89年开始 头，研究药物分支的发育化学疗法部分 癌症治疗，国家癌症研究所。 Leyland-Jones博士在Winship Cancer Institute领导努力的能力是 通过他先前的高级职位和作为首要翻译的经验证明 科学家。在担任麦吉尔综合癌症中心主任的任期期间。 Leyland-Jones领导了临床试验操作的开发，该操作将研究与五个 临床试验合作组织和40多家制药公司。在Dr. Leyland-Jones的方向，麦吉尔的癌症相关临床试验包括100多个 任何一次方案，并通过九个多学科疾病部分进行结构 在整个癌症中心。在NCI期间，他负责总体 从IN的各个过渡阶段开发了大约70种抗癌化合物 体外筛选到第三阶段临床试验。他在肿瘤学临床方面的药物遗传学专业知识 L/LL抗癌代理商中的试验和生物标志物终点强调了他的出色 领导WCI及其科学计划并共享核心资源的背景 追求NCI为癌症中心。 Leyland-Jones博士在担任Winship Cancer Institute主任的职务中提供了总体。 WCI的领导，其科学计划，其共享核心资源，其组织及其 行政。 Leyland-Jones博士代表WCI的战略规划和领导力 伍德拉夫健康科学中心和医学院的委员会 主席理事会。董事的权威在 上一节。 Leyland-Jones博士控制空间，设施，筹款分配， 预算和Winship癌症研究所的其他资源。与个别部门共同 椅子，他有能力将新教师招募到埃默里大学，并获得会员资格 委员会他监督WCI的会员资格。作为矩阵中心的主任，Leyland-博士 琼斯与医学院的其他院长和部门主席紧密互动， 伍德拉夫健康科学中心和埃默里学院的护理和公共卫生。他 也代表WCI与我们的社区合作伙伴合作，包括美国 癌症协会，疾病预防控制中心，佐治亚州癌症联盟，佐治亚研究联盟，佐治亚研究所 用于技术，莫尔豪斯医学院，GA核心和其他机构 乔治亚州。 Leyland-Jones博士提供了与国家癌症研究所的界面， 国家和地方媒体，以及患者倡导组织和基金会。 Leyland-Jones博士致力于全职担任WCI董事，并担任校长 CCSG的调查员，但CCSG预算仅支持他的25％的努力。他会的 提供高级领导，监督，战略规划以及对进步的持续评估 在项目期间实现既定目标和目标。